N/A
N=104
Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Bottom Line
View on ClinicalTrials.gov: NCT04505540 ↗Enrolled (actual)
104
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcome: Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Bridge Clinic (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Vermont
- Primary completion
- Oct 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Self-reported Treatment Retention |
51 | — |
| PRIMARY Number of Participants With Self-reported Treatment Retention |
51 | — |
| PRIMARY Number of Participants With Self-reported Treatment Retention |
51 | — |
| SECONDARY Number of Participants With Illicit Opioid Use |
1 | — |
| SECONDARY Number of Participants With Illicit Opioid Use |
1 | — |
| SECONDARY Number of Participants With Illicit Opioid Use |
1 | — |
Summary
The purpose of this study is 1) to evaluate whether emergency department-initiated medically assisted treatment with Buprenorphine/Naloxone in patients presenting with opioid use disorder will produce positive outcomes at 1 week, 3 months and 6 months after treatment initiation.
Eligibility Criteria
Inclusion Criteria
- Patient at Emergency Department
- Diagnosis opioid use disorder according to criteria Diagnostic and Statistical Manual (DSM) 5
Exclusion Criteria
- Participating in alternate treatment program for opioid use disorder
- Prisoner
- Inability to communicate
- Psychosis
- Suicidality
- History of Buprenorphine injection
- Critical Illness
Data sourced from ClinicalTrials.gov (NCT04505540). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.